These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 10397563)

  • 1. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
    Kuritzkes DR; Marschner I; Johnson VA; Bassett R; Eron JJ; Fischl MA; Murphy RL; Fife K; Maenza J; Rosandich ME; Bell D; Wood K; Sommadossi JP; Pettinelli C
    AIDS; 1999 Apr; 13(6):685-94. PubMed ID: 10397563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
    AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
    Kuritzkes DR; Bassett RL; Johnson VA; Marschner IC; Eron JJ; Sommadossi JP; Acosta EP; Murphy RL; Fife K; Wood K; Bell D; Martinez A; Pettinelli CB
    AIDS; 2000 Jul; 14(11):1553-61. PubMed ID: 10983642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.
    Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; Diaz C; Yogev R; McKinney RE; Abrams EJ; Mofenson LM
    Pediatrics; 1999 May; 103(5):e62. PubMed ID: 10224206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
    Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
    Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
    AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
    Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P;
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
    Ungsedhapand C; Srasuebkul P; Cardiello P; Ruxrungtham K; Ratanasuwan W; Kroon ED; Tongtalung M; Juengprasert N; Ubolyam S; Siangphoe U; Emery S; Lange JM; Cooper DA; Phanuphak P;
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):693-701. PubMed ID: 15167288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
    Montaner JS; DeMasi R; Hill AM
    AIDS; 1998 Mar; 12(5):F23-8. PubMed ID: 9543436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
    ; Ratsela A; Polis M; Dhlomo S; Emery S; Grandits G; Khabo P; Khanyile T; Komati S; Neaton JD; Naidoo LC; Magongoa D; Qolohle D
    J Infect Dis; 2010 Nov; 202(10):1529-37. PubMed ID: 20942650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298).
    Pollard RB; Tierney C; Havlir D; Tebas P; Fox L; Smeaton L; Richman D; Friedland GH
    AIDS Res Hum Retroviruses; 2002 Jul; 18(10):699-704. PubMed ID: 12167276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
    J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
    AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
    Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA
    AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
    HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.